Proof of efficacy trials: Choosing the dose

Epilepsy Research

Volumn 45, Issue 1-3, 2001, Pages 23-28

  Pledger, Gordon ^a  

^a R W JOHNSON PHARMACEUTICAL RES I   (United States)

Author keywords

Antiepileptic drugs; Dose; Dose titration; Proof of efficacy trials

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; TIAGABINE; TOPIRAMATE; VIGABATRIN;

CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERANCE; DRUG USE; EPILEPSY; HUMAN; METHODOLOGY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TITRIMETRY;

ANIMALS; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY; HUMANS; RESEARCH DESIGN;

EID: 0034920789     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(01)00208-X     Document Type: Conference Paper

References (14)

1. Clinical trial design for new antiepileptic drugs: Determination of dose and titration schedules
2. Open dose ranging trial of flunarazine as add-on therapy in epilepsy
3. Double-blind crossover trial of lamotrigine as add-on therapy in intractable epilepsy
4. Comparison of two upward titration rates in initiation of therapy with topiramate
5. Guidelines for clinical evaluation of antiepileptic drugs
6. Topiramate as adjunctive therapy in pediatric patients with partial-onset seizures
7. The art of antiepileptic trial design
8. Strategies for the development of drugs for pharmacoresistant epilepsies
9. Prototype antiepileptic drug clinical development plan
10. Flunarizine for treatment of partial seizures: Results of a concentration-controlled trial
11. Randomization, PK-controlled dosing and titration: An integrated approach for designing clinical trials
12. Increasing plasma concentration tolerability study of flunarizine in co-medicated epileptic patients